Use of Biomarkers for Diagnosing and Assessing Treatment Response in Noncirrhotic NASH Trials-D2-AM

แชร์
ฝัง
  • เผยแพร่เมื่อ 29 ต.ค. 2023
  • This workshop assisted the FDA in identifying current knowledge gaps for using NITs as diagnostic biomarkers and reasonably likely surrogates, as well as provided a framework for additional data that are needed to fill these knowledge gaps. The primary focus of this workshop was “non-cirrhotic NASH/MASH population with advanced (i.e., Stage 2 or Stage 3) liver fibrosis.”
    -Session One: Considerations for Surrogate Endpoint Development.
    -Session Two: Imaging Based Biomarkers for Noncirrhotic NASH Clinical Trial.
    Timestamps
    00:11 - Welcome Remarks, Recap, and Introduction
    06:28 - Biomarkers and Surrogate Endpoints in the Regulatory Framework
    11:37 - Session Two Introductions
    13:54 - Ultrasound Based Liver Stiffness
    29:08 - Magnetic Resonance Elastography (MRE)
    49:28 - Corrected T1 (cT1) MRI and MRI-PDFF
    01:09:14 - Session Two Q&A Discussion Panel
    Speakers:
    Insook Kim, PhD
    Master Scientist
    Division of Inflammation and Immune Pharmacology (DIIP)
    Office of Clinical Pharmacology (OCP)
    Office of Translational Sciences (OTS)
    Center for Drug Evaluation and Research (CDER) | FDA
    Rebecca Hager, PhD
    Lead Mathematical Statistician
    Division of Biometrics III (DBIII)
    Office of Biostatistics (OB)
    OTS | CDER | FDA
    Abbas Bandukwala, MS
    Commander
    United States Public Health Service (USPHS)
    Science Policy Analyst
    Biomarker Qualification Program
    Office of New Drugs (OND) | CDER | FDA
    Philip Newsome MD, PhD, FRCPE
    Director, Centre for Liver & GI Research
    University of Birmingham
    Claude Sirlin, MD
    Professor of Radiology
    Liver Imaging Group
    University of California, San Diego
    Scott B. Reeder, MD, PhD
    Professor and Senior Vice Chair (Research)
    Chief of Magnetic Resonance Imaging
    Departments of Radiology, Medical Physics, Biomedical Engineering, Medicine, and Emergency Medicine University of Wisconsin-Madison
    Panelists:
    Abbas Bandukwala, Phillip Newsome, Claude Sirlin, Scott Reeder
    and
    Daniel Krainak, PhD
    Assistant Director
    Division of Radiological Imaging & Radiation Therapy Devices
    Office of Radiological Health (OHT8)
    Office of Product Evaluation and Quality (OPEQ)
    Center for Devices and Radiological Health (CDRH) | FDA
    Rajarshi Banerjee
    DPhil, MPH, MA, BM BCh, MRCP
    CEO, Perspectum Ltd
    Honorary Consultant Physician, Oxford University Hospitals NHS Trust

    Richard L. Ehman, MD
    Professor of Radiology
    Blanche & Richard Erlanger Endowed Professor of Medical Research
    Mayo Clinic
    David T. Fetzer, MD
    Assistant Professor, Abdominal Imaging Division
    Medical Director, Ultrasound
    Department of Radiology
    UT Southwestern Medical Center (UTSW)
    Céline Fournier, PhD
    Chief Medical Officer
    Echosens
    Lori E Dodd, PhD
    Mathematical Statistician
    Clinical Trials Research Section
    Biostatistics Research Branch
    Division of Clinical Research
    NIAID | National Institutes of Health (NIH)
    Learn more at: www.fda.gov/drugs/news-events...
    -----------------------
    FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
    Upcoming Training - www.fda.gov/cdersbia
    SBIA Listserv - public.govdelivery.com/accoun...
    SBIA 2022 Playlist - • 2022 CDER Small Busine...
    SBIA LinkedIn -  / cder-small-business-an...
    SBIA Training Resources - www.fda.gov/cdersbialearn
    Twitter -  / fda_drug_info
    Email - CDERSBIA@fda.hhs.gov
    Phone - (301) 796-6707 I (866) 405-5367
  • วิทยาศาสตร์และเทคโนโลยี

ความคิดเห็น •